The different impact of a high fat diet on dystrophic mdx and control C57Bl/10 mice

PLoS Currents

Volumn , Issue , 2011, Pages

  Radley Crabb, Hannah G ^a   Fiorotto, Marta L ^b   Grounds, Miranda D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; CREATINE KINASE; CYTOKINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA;

ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY FAT; CALORIC INTAKE; CONTROLLED STUDY; CYTOKINE RELEASE; DIET SUPPLEMENTATION; DISEASE SEVERITY; DUCHENNE MUSCULAR DYSTROPHY; ENERGY METABOLISM; FAT INTAKE; GASTROCNEMIUS MUSCLE; LEAN BODY WEIGHT; LIPID DIET; LIPID METABOLISM; LIPID STORAGE; MALE; MOUSE; MUSCLE CELL; MUSCLE CONTRACTION; MUSCLE FUNCTION; MUSCLE INJURY; MUSCLE NECROSIS; MUSCULAR DYSTROPHY; NONHUMAN; PROTEIN DIET; PROTEIN INTAKE; RUNNING; SEDENTARY LIFESTYLE; WEIGHT GAIN; ADIPOCYTE; EXERCISE; GENE EXPRESSION; HISTOLOGY; MUSCLE FIBRIL; SITTING;

EID: 84867467533     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/currents.RRN1276     Document Type: Article

References (74)

1. Radley HG, Davies MJ, and Grounds MD. Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment. Neuromuscul Disord. 2008; 18: 227-38.
2. Tidball JG and Wehling-Henricks M. The role of free radicals in the pathophysiology of muscular dystrophy. J Appl Physiol. 2007; 102: 1677-86.
3. Whitehead NP, Pham C, Gervasio OL, and Allen DG. N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice. J Physiol. 2008; 586: 2003-14.
4. Kuznetsov AV, Winkler K, Wiedemann FR, von Bossanyi P, Dietzmann K, and Kunz WS. Impaired mitochondrial oxidative phosphorylation in skeletal muscle of the dystrophin-deficient mdx mouse. Mol Cell Biochem. 1998; 183: 87-96.
5. Even PC, Decrouy A, and Chinet A. Defective regulation of energy metabolism in mdx-mouse skeletal muscles. Biochem J. 1994; 304 (Pt 2): 649-54.
6. Evans NP, Misyak SA, Robertson JL, Bassaganya-Riera J, and Grange RW. Dysregulated intracellular signaling and inflammatory gene expression during initial disease onset in Duchenne muscular dystrophy. Am J Phys Med Rehabil. 2009; 88: 502-22.
7. Davidson ZE and Truby H. A review of nutrition in Duchenne muscular dystrophy. J Hum Nutr Diet. 2009; 22: 383-93.
8. Radley HG, De Luca A, Lynch GS, and Grounds MD. Duchenne muscular dystrophy: Focus on pharmaceutical and nutritional interventions. Int J Biochem Cell Biol. 2007; 39: 469-77.
9. Manzur AY, Kuntzer T, Pike M, and Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane database of systematic reviews (Online). 2008; CD003725.
10. Angelini C. The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle Nerve. 2007; 36: 424-35.
11. Biggar WD, Harris VA, Eliasoph L, and Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord. 2006; 16: 249-255.
12. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, and Constantin C. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010; 9: 77-93.
13. Pichavant C, Aartsma-Rus A, Clemens PR, Davies KE, Dickson G, Takeda S, Wilton SD, Wolff JA, Wooddell CI, Xiao X, and Tremblay JP. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Molecular therapy: the journal of the American Society of Gene Therapy. 2011; 19: 830-40.
14. Wells DJ. Treatments for muscular dystrophy: increased treatment options for Duchenne and related muscular dystropies. Gene Ther. 2008; 15: 1077-8.
15. Guglieri M and Bushby K. Molecular treatments in Duchenne muscular dystrophy. Curr Opin Pharmacol. 2010.
16. Manzur AY and Muntoni F. Diagnosis and new treatments in muscular dystrophies. J Neurol Neurosurg Psychiatry. 2009; 80: 706-14.
17. Nagaraju K and Willmann R. Developing standard procedures for murine and canine efficacy studies of DMD therapeutics: report of two expert workshops on Pre-clinical testing for Duchenne dystrophy: Washington DC, October 27th-28th 2007 and Zurich, June 30th-July 1st 2008. Neuromuscul Disord. 2009; 19: 502-6.
18. Grounds MD, Radley HG, Lynch GS, Nagaraju K, and De Luca A. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis. 2008; 31: 1-19.
19. Vainzof M, Ayub-Guerrieri D, Onofre PC, Martins PC, Lopes VF, Zilberztajn D, Maia LS, Sell K, and Yamamoto LU. Animal models for genetic neuromuscular diseases. J Mol Neurosci. 2008; 34: 241-8.
20. Grounds MD. Two-tiered hypotheses for Duchenne muscular dystrophy. Cell Mol Life Sci. 2008; 65: 1621-5.
21. Willmann R, Possekel S, Dubach-Powell J, Meier T, and Ruegg MA. Mammalian animal models for Duchenne muscular dystrophy. Neuromuscul Disord. 2009; 19: 241-9.
22. El-Shafey AF, Armstrong AE, Terrill JR, Grounds MD, and Arthur PG. Screening for increased protein thiol oxidation in oxidatively stressed muscle tissue. Free radical research. 2011; 45: 991-9.
23. Dupont-Versteegden EE, Baldwin RA, McCarter RJ, and Vonlanthen MG. Does muscular dystrophy affect metabolic rate? Journal of Neurological Sciences. 1994; 121: 203-207.
24. Landisch RM, Kosir AM, Nelson SA, Baltgalvis KA, and Lowe DA. Adaptive and nonadaptive responses to voluntary wheel running by mdx mice. Muscle Nerve. 2008; 38: 1290-303.
25. Passaquin AC, Renard M, Kay L, Challet C, Mokhtarian A, Wallimann T, and Ruegg UT. Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromuscul Disord. 2002; 12: 174-182.
26. Han R, Grounds MD, and Bakker AJ. Measurement of sub-membrane [Ca(2+)] in adult myofibers and cytosolic [Ca(2+)] in myotubes from normal and mdx mice using the Ca(2+) indicator FFP-18. Cell Calcium. 2006; 40: 299-307.
27. Whitehead NP, Yeung EW, and Allen DG. Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clin Exp Pharmacol Physiol. 2006; 33: 657-662.
28. MacLennan PA and Edwards RH. Protein turnover is elevated in muscle of mdx mice in vivo. Biochem J. 1990; 268: 795-7.
29. Griggs RC and Rennie MJ. Muscle wasting in muscular dystrophy: decreased protein synthesis or increased degradation? Ann Neurol. 1983; 13: 125-32.
30. Zanardi MC, Tagliabue A, Orcesi S, Berardinelli A, Uggetti C, and Pichiecchio A. Body composition and energy expenditure in Duchenne muscular dystrophy. Eur J Clin Nutr. 2003; 57: 273-8.
31. Helliwell TR, MacLennan PA, McArdle A, Edwards RHT, and Jackson MJ. Fasting increases the extent of muscle necrosis in the mdx mouse. Clinical Science. 1996; 90: 467-472.
32. Bogdanovich Sea. Therapeutics for Duchenne muscular dystrophy: current approaches and future directions. Journal of Molecular Medicine. 2004; 82: 102-115.
33. Pearlman JP and Fielding RA. Creatine monohydrate as a therapeutic aid in muscular dystrophy. Nutrition Review. 2006; 64: 80-8.
34. Leighton S. Nutrition for boys with Duchenne muscular dystrophy. Nutrition and Dietetics. 2003; 60: 11-15.
35. Escolar DM, Buyse G, Henricson E, Leshner R, Florence J, Mayhew J, Tesi-Rocha C, Gorni K, Pasquali L, Patel KM, McCarter R, Huang J, Mayhew T, Bertorini T, Carlo J, Connolly AM, Clemens PR, Goemans N, Iannaccone ST, Igarashi M, Nevo Y, Pestronk A, Subramony SH, Vedanarayanan VV, and Wessel H. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol. 2005; 58: 151-5.
36. Tarnopolsky MA, Mahoney DJ, Vajsar J, Rodriguez C, Doherty TJ, Roy BD, and Biggar D. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology. 2004; 62: 1771-7.
37. De Luca A, Pierno S, Liantonio A, Cetrone M, Camerino C, Fraysse B, Mirabella M, Servidei S, Ruegg UT, and Conte Camerino D. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. Journal of Pharmacological and Experimental Therapeutics. 2003; 304: 453-63.
38. Granchelli JA, Pollina C, and Hudecki MS. Pre-clinical screening of drugs using the mdx mouse. Neuromusclular Disorders. 2000; 10: 235-239.
39. Payne ET, Yasuda N, Bourgeois JM, Devries MC, Rodriguez MC, Yousuf J, and Tarnopolsky MA. Nutritional therapy improves function and complements corticosteroid intervention in mdx mice. Muscle Nerve. 2006; 33: 66-77.
40. Cozzoli A, Rolland JF, Capogrosso RF, Sblendorio VT, Longo V, Simonetti S, Nico B, and De Luca A. Evaluation of Potential Synergistic Action of a Combined Treatment with Alpha-Methyl-Prednisolone and Taurine on the Mdx Mouse Model of Duchenne Muscular Dystrophy. Neuropathol Appl Neurobiol. 2010;
41. Zdanowicz MM, Slonim AE, Bilaniuk I, O'Connor MM, Moyse J, and Teichberg S. High protein diet has beneficial effects in murine muscular dystrophy. J Nutr. 1995; 125: 1150-8.
42. Grounds MD, Radley HG, Gebski BL, Bogoyevitch MA, and Shavlakadze T. Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscle. Clin Exp Pharmacol Physiol. 2008; 35: 846-51.
43. Tidball JG and Wehling-Henricks M. Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis. Curr Opin Rheumatol. 2005; 17: 707-713.
44. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol. 2004; 15: 2792-800.
45. Pedersen BK. IL-6 signalling in exercise and disease. Biochem Soc Trans. 2007; 35: 1295-7.
46. Stienstra R, Duval C, Muller M, and Kersten S. PPARs, Obesity, and Inflammation. PPAR Res. 2007; 2007: 95974.
47. Zierath JR and Hawley JA. Skeletal muscle fiber type: influence on contractile and metabolic properties. PLoS Biol. 2004; 2: e348.
48. Liang H and Ward WF. PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ. 2006; 30: 145-51.
49. Hodgetts S, Radley H, Davies M, and Grounds MD. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice. Neuromuscul Disord. 2006; 16: 591-602.
50. Radley HG and Grounds MD. Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in mdx mice. Neurobiol Dis. 2006; 23: 387-97.
51. Hara H, Nolan PM, Scott MO, Bucan M, Wakayama Y, and Fischbeck KH. Running endurance abnormality in mdx mice. Muscle Nerve. 2002; 25: 207-11.
52. Shavlakadze T, Chai J, Maley K, Cozens G, Grounds G, Winn N, Rosenthal N, and Grounds MD. A growth stimulus is needed for IGF-1 to induce skeletal muscle hypertrophy in vivo. J Cell Sci. 2010; 123: 960-71.
53. Turpin SM, Ryall JG, Southgate R, Darby I, Hevener AL, Febbraio MA, Kemp BE, Lynch GS, and Watt MJ. Examination of 'lipotoxicity' in skeletal muscle of high-fat fed and ob/ob mice. J Physiol. 2009; 587: 1593-605.
54. Radley-Crabb H, Terrill J, Shavlakadze T, Tonkin J, Arthur P, and Grounds M. A single 30min treadmill exercise session is suitable for 'proof-of concept studies' in adult mdx mice: A comparison of the early consequences of two different treadmill protocols. Neuromuscular disorders: NMD. 2011.
55. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, Rawat R, Van Der Meulen JH, Cha HJ, Pistilli EE, Partridge TA, Hoffman EP, and Nagaraju K. Preclinical drug trials in the mdx mouse: Assessment of reliable and sensitive outcome measures. Muscle Nerve. 2009; 39: 591-602.
56. Alexander J, Chang GQ, Dourmashkin JT, and Leibowitz SF. Distinct phenotypes of obesity-prone AKR/J, DBA2J and C57BL/6J mice compared to control strains. International journal of obesity (2005). 2006; 30: 50-9.
57. Buettner R, Scholmerich J, and Bollheimer LC. High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity Silver Spring, Md. 2007; 15: 798-808.
58. Pedersen BK. Muscle-to-fat interaction: a two-way street? J Physiol. 2010; 588: 21.
59. Peter AK and Crosbie RH. Hypertrophic response of Duchenne and limb-girdle muscular dystrophies is associated with activation of Akt pathway. Exp Cell Res. 2006; 312: 2580-91.
60. Anderson JE, Ovalle WK, and Bressler BH. Electron microscopic and autoradiographic characterization of hindlimb muscle regeneration in the mdx mouse. Anat Rec. 1987; 219: 243-257.
61. Coulton GR, Curtin NA, Morgan JE, and Partridge TA. The mdx mouse skeletal muscle myopathy: II. Contractile properties. Neuropathol Appl Neurobiol. 1988; 14: 299-314.
62. Mokhtarian A, Decrouy A, Chinet A, and Even PC. Components of energy expenditure in the mdx mouse model of Duchenne muscular dystrophy. Pflugers Arch. 1996; 431: 527-32.
63. Connolly AM, Keeling RM, Mehta S, Pestronk A, and Sanes JR. Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin alpha2-deficient mice. Neuromuscul Disord. 2001; 11: 703-12.
64. Griffiths RD and Edwards RH. A new chart for weight control in Duchenne muscular dystrophy. Arch Dis Child. 1988; 63: 1256-8.
65. Grounds MD and Shavlakadze T. Growing muscle has different sarcolemmal properties from adult muscle: a proposal with scientific and clinical implications: reasons to reassess skeletal muscle molecular dynamics, cellular responses and suitability of experimental models of muscle disorders. BioEssays: news and reviews in molecular, cellular and developmental biology. 2011; 33: 458-68.
66. Shavlakadze T and Grounds M. Of bears, frogs, meat, mice and men: complexity of factors affecting skeletal muscle mass and fat. BioEssays. 2006; 28: 994-1009.
67. Conte Camerino D, Tricarico D, Pierno S, Desaphy JF, Liantonio A, Pusch M, Burdi R, Camerino C, Fraysse B, and De Luca A. Taurine and skeletal muscle disorders. Neurochem Res. 2004; 29: 135-42.
68. Curi R, Lagranha CJ, Doi SQ, Sellitti DF, Procopio J, Pithon-Curi TC, Corless M, and Newsholme P. Molecular mechanisms of glutamine action. Journal of cellular physiology. 2005; 204: 392-401.
69. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, and Karin M. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005; 11: 191-8.
70. Ehrenborg E and Krook A. Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta. Pharmacol Rev. 2009; 61: 373-93.
71. Piers AT, Lavin T, Radley-Crabb HG, Bakker AJ, Grounds MD, and Pinniger GJ. Blockade of TNF in vivo using cV1q antibody reduces contractile dysfunction of skeletal muscle in response to eccentric exercise in dystrophic mdx and normal mice. Neuromuscul Disord. 2011; 21: 132-41.
72. Davies KE and Khurana TS. A new way to regulate the NMJ. Nat Med. 2007; 13: 538-9.
73. Handschin C, Kobayashi YM, Chin S, Seale P, Campbell KP, and B.M. S. PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes Dev. 2007; 21: 770-783.
74. Miura P, Chakkalakal JV, Boudreault L, Belanger G, Hebert RL, Renaud JM, and Jasmin BJ. Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice. Hum Mol Genet. 2009; 18: 4640-9.